miRNA Regulation of Macrophages after Spinal Cord Injury

脊髓损伤后巨噬细胞的 miRNA 调控

基本信息

  • 批准号:
    8427903
  • 负责人:
  • 金额:
    $ 22.88万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-09-01 至 2014-08-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): After spinal cord injury (SCI), "M1" (pro-inflammatory) and "M2" (anti-inflammatory) macrophages populate the lesion site. M1 macrophages, which cause neurotoxicity and hamper neuroregeneration, persist in SCI lesions. In contrast, M2 macrophages, which support axon growth and are not neurotoxic, disappear after a few days. This progressive "loss" of M2 macrophages is thought to be due to the conversion of newly activated microglia and infiltrating monocytes into M1 cells as they respond to pro- inflammatory cues in the acute SCI environment. This phenomenon has so far impeded attempts to harness the regenerative power of M2 macrophages to improve SCI recovery. Therefore, therapeutic strategies that suppress M1 and enhance M2 macrophages in the highly inflammatory SCI environment are actively sought. We have recently identified a specific microRNA (miRNA) required for M1 differentiation. miRNA are small RNAs that post-transcriptionally regulate gene expression networks, contributing to cell differentiation and lineage choice. We predict that specific modulation of this miRNA will reduce the ratio of M1/M2 macrophages after SCI, thereby improving the efficiency and extent of tissue repair after SCI. This hypothesis will be tested in an in vivo model of SCI, using mice deficient for this specific mRNA, and developing a pharmacologic strategy to modulate macrophage phenotype with specific miRNA inhibitors. Since miRNA can be manipulated to treat human disease, these studies will provide the basis for development of promising new therapies. In addition, understanding how this specific miRNA controls inflammation through regulation of the M1/M2 balance will have important implications to regulation of macrophage-mediated inflammation (or immune suppression) in other conditions, such as atherosclerosis, wound healing and cancer. PUBLIC HEALTH RELEVANCE: These studies investigate the role of the small RNA miR-155 in spinal cord injury inflammation, pathology and functional recovery. The effects of macrophage-targeted miR-155 loss in control of inflammation and enhancement of neuroregeneration will be assessed in a rodent model of spinal cord injury. These studies will likely impact therapies for spinal cord injury and other conditions such as atherosclerosis, wound healing and cancer.
描述(由申请人提供):脊髓损伤(SCI)后,“M1”(促炎)和“M2”(抗炎)巨噬细胞聚集在病变部位。M1巨噬细胞,引起神经毒性和阻碍神经再生,持续在SCI病变。相反,支持轴突生长且无神经毒性的M2巨噬细胞在几天后消失。M2巨噬细胞的这种进行性“损失”被认为是由于新活化的小胶质细胞和浸润的单核细胞在急性SCI环境中响应促炎性线索时转化为M1细胞。到目前为止,这种现象阻碍了利用M2巨噬细胞的再生能力来改善SCI恢复的尝试。因此,积极寻求在高度炎症性SCI环境中抑制M1和增强M2巨噬细胞的治疗策略。我们最近发现了M1分化所需的特定microRNA(miRNA)。miRNA是转录后调节基因表达网络的小RNA,有助于细胞分化和谱系选择。我们预测,这种miRNA的特异性调节将降低SCI后M1/M2巨噬细胞的比例,从而提高SCI后组织修复的效率和程度。这一假设将在SCI的体内模型中进行测试,使用缺乏这种特定mRNA的小鼠,并开发出一种用特定miRNA抑制剂调节巨噬细胞表型的药理学策略。由于可以操纵miRNA来治疗人类疾病,这些研究将为开发有前途的新疗法提供基础。此外,了解这种特定的miRNA如何通过调节M1/M2平衡来控制炎症,将对调节其他疾病(如动脉粥样硬化,伤口愈合和癌症)中巨噬细胞介导的炎症(或免疫抑制)具有重要意义。 公共卫生关系:这些研究探讨了小RNA miR-155在脊髓损伤炎症、病理学和功能恢复中的作用。将在脊髓损伤的啮齿动物模型中评估巨噬细胞靶向的miR-155损失在控制炎症和增强神经再生中的作用。这些研究可能会影响脊髓损伤和其他疾病的治疗,如动脉粥样硬化,伤口愈合和癌症。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Mireia Guerau-de-Arellano其他文献

Mireia Guerau-de-Arellano的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Mireia Guerau-de-Arellano', 18)}}的其他基金

Novel knockout models to analyze CD38 function
用于分析 CD38 功能的新型敲除模型
  • 批准号:
    10177865
  • 财政年份:
    2020
  • 资助金额:
    $ 22.88万
  • 项目类别:
Novel knockout models to analyze CD38 function
用于分析 CD38 功能的新型敲除模型
  • 批准号:
    10063339
  • 财政年份:
    2020
  • 资助金额:
    $ 22.88万
  • 项目类别:
Epigenetic modulation of T cell tolerance in Multiple Sclerosis autoimmunity
多发性硬化症自身免疫中 T 细胞耐受的表观遗传调节
  • 批准号:
    9926829
  • 财政年份:
    2016
  • 资助金额:
    $ 22.88万
  • 项目类别:
Novel Epigenetic Modifier Inhibitor Drugs for T cell Modulation in Multiple Sclerosis
用于多发性硬化症 T 细胞调节的新型表观遗传修饰抑制剂药物
  • 批准号:
    9211542
  • 财政年份:
    2016
  • 资助金额:
    $ 22.88万
  • 项目类别:
Epigenetic modulation of T cell tolerance in Multiple Sclerosis autoimmunity
多发性硬化症自身免疫中 T 细胞耐受的表观遗传调节
  • 批准号:
    9301459
  • 财政年份:
    2016
  • 资助金额:
    $ 22.88万
  • 项目类别:
miRNA Regulation of Macrophages after Spinal Cord Injury
脊髓损伤后巨噬细胞的 miRNA 调控
  • 批准号:
    8539110
  • 财政年份:
    2012
  • 资助金额:
    $ 22.88万
  • 项目类别:

相似海外基金

Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 22.88万
  • 项目类别:
    Fellowship
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 22.88万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 22.88万
  • 项目类别:
    Collaborative R&D
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 22.88万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 22.88万
  • 项目类别:
    Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 22.88万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 22.88万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 22.88万
  • 项目类别:
    Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 22.88万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Collaborative Research: Changes and Impact of Right Ventricle Viscoelasticity Under Acute Stress and Chronic Pulmonary Hypertension
合作研究:急性应激和慢性肺动脉高压下右心室粘弹性的变化和影响
  • 批准号:
    2244994
  • 财政年份:
    2023
  • 资助金额:
    $ 22.88万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了